TIDMWWH

Worldwide Healthcare Trust PLC

26 March 2018

London, UK, 26 March 2018

Edison issues review on Worldwide Healthcare Trust (WWH)

Worldwide Healthcare Trust (WWH) is managed by OrbiMed Capital, a leading specialist healthcare investment company. Since December 2017, following the departure of Sam Isaly, its lead manager is Sven Borho, who is a founding partner of OrbiMed and has been involved with the management of WWH since the trust's launch in April 1995. Borho is bullish on the outlook for the global healthcare sector due to continued innovation, a benign regulatory environment, an expected acceleration in mergers and acquisitions, and inexpensive company valuations. WWH has a positive long-term performance track record. Its NAV and share price total returns have exceeded the MSCI World Health Care index total returns over one, three, five and 10 years.

WWH's share price discount to cum-income NAV has narrowed meaningfully from 13.0% at end-June 2016 following the UK's European referendum, and in recent months the trust has been trading close to NAV. Over the last 12 months, WWH has traded at an average premium of 0.3%, which compares to the average discounts over the last three, five and 10 years of 3.3%, 3.4% and 5.7% respectively. While WWH aims to generate long-term capital growth, rather than income, the trust pays dividends regularly twice a year; its current yield is 0.9%.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Mel Jenner, +44 (0)20 3077 5720

Sarah Godfrey, +44 (0)20 3681 2519

investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

   LinkedIn        https://www.linkedin.com/company/edison-investment-research 
   Twitter           www.twitter.com/Edison_Inv_Res 
   YouTube       www.youtube.com/edisonitv

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAJFMTTMBMTBAP

(END) Dow Jones Newswires

March 26, 2018 08:11 ET (12:11 GMT)

Finsbury Worldwide Pharm (LSE:FWP)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Finsbury Worldwide Pharm Charts.
Finsbury Worldwide Pharm (LSE:FWP)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Finsbury Worldwide Pharm Charts.